Analysts have been eager to weigh in on the Healthcare sector with new ratings on Johnson & Johnson (JNJ – Research Report) and Aveanna Healthcare Holdings (AVAH – Research Report).
Johnson & Johnson (JNJ)
RBC Capital analyst Shagun Singh Chadha reiterated a Buy rating on Johnson & Johnson on March 15 and set a price target of $181.00. The company’s shares closed last Friday at $158.18.
According to TipRanks.com, Chadha is a 2-star analyst with an average return of
Currently, the analyst consensus on Johnson & Johnson is a Moderate Buy with an average price target of $178.85, representing a 13.2% upside. In a report issued on March 13, Cantor Fitzgerald also maintained a Buy rating on the stock with a $215.00 price target.
See today’s best-performing stocks on TipRanks >>
Aveanna Healthcare Holdings (AVAH)
RBC Capital analyst Ben Hendrix maintained a Hold rating on Aveanna Healthcare Holdings yesterday and set a price target of $3.00. The company’s shares closed last Friday at $2.48.
According to TipRanks.com, Hendrix is a 3-star analyst with an average return of
Aveanna Healthcare Holdings has an analyst consensus of Hold, with a price target consensus of $3.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on JNJ:
- Legend Biotech notes ODAC recommends Carvykti for earlier treatment of myeloma
- J&J says ODAC recommends Carvykti for earlier treatment of myeloma
- FDA advisors vote in favor of expanding label of J&J’s Carvykti
- JPMorgan biotech/pharma analysts hold an analyst/industry conference call
- Foot Locker appoints Cindy Carlisle as Chief Human Resources Officer
